Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic factors for the development of Alzheimer disease in the Cherokee Indian.
Rosenberg RN, Richter RW, Risser RC, Taubman K, Prado-Farmer I, Ebalo E, Posey J, Kingfisher D, Dean D, Weiner MF, Svetlik D, Adams P, Honig LS, Cullum CM, Schaefer FV, Schellenberg GD. Rosenberg RN, et al. Among authors: richter rw. Arch Neurol. 1996 Oct;53(10):997-1000. doi: 10.1001/archneur.1996.00550100071017. Arch Neurol. 1996. PMID: 8859062
Comparison of Alzheimer's disease in Native Americans and Whites.
Weiner MF, Rosenberg RN, Svetlik D, Hynan LS, Womack KB, White C 3rd, Good S, Fuller C, Wharton D, Richter R. Weiner MF, et al. Int Psychogeriatr. 2003 Dec;15(4):367-75. doi: 10.1017/s104161020300961x. Int Psychogeriatr. 2003. PMID: 15000416
A phase 3 trial of IV immunoglobulin for Alzheimer disease.
Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study. Relkin NR, et al. Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5. Neurology. 2017. PMID: 28381506 Free PMC article. Clinical Trial.
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. Coric V, et al. Among authors: richter rw. Arch Neurol. 2012 Nov;69(11):1430-40. doi: 10.1001/archneurol.2012.2194. Arch Neurol. 2012. PMID: 22892585 Clinical Trial.
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.
Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F. Dodel R, et al. Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31. Lancet Neurol. 2013. PMID: 23375965 Free PMC article. Clinical Trial.
57 results